In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion

http://

Latest From Celltrion

TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza

Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.

Clinical Trials Business Strategies

Celltrion Gets Ready To Push Tocilizumab Into Phase III

Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.

Biosimilars Clinical Trials

Keeping Track: Incyte’s Opzelura Earns First Vitiligo Claim; NDAs From Apellis, Acadia

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

United States BioPharmaceutical

Following Positive IIb Study Data, Can 180 Life Sciences Clear The Next Regulatory Hurdle?

180 Life Sciences has found that adalimumab can effectively treat nodule hardness and size in Dupuytren’s disease during a Phase IIb study. But, the company’s CEO Jim Woody tells Generics Bulletin, regulators in the UK and US have requested more information before they will press on with authorization.

Regulation Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register